1IY0.F Monopar Therapeutics Inc.

Healthcare Biotechnology Frankfurt Exchange
63.80 EUR
Close of Nov 11, 2026
41.70 103.40
Market cap
EUR 428M
P/E
-
P/B
3.61x
ROE
-14.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 1IY0.F undervalued?

Graham number

The Graham number of Monopar Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Monopar Therapeutics Inc. fundamental analysis

No fundamental analysis for Monopar Therapeutics Inc. yet.

Monopar Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Monopar Therapeutics Inc.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase…

Full company profile